Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has reported revenues of $7.9bn for the third quarter ended 30 September 2010, compared to $8.2bn for the same period in 2009.
Subscribe to our email newsletter
Revenue in markets outside the US increased by 7%, including a 14% increase in Emerging Markets.
Revenue in Western Europe was up 3%. Revenue in Established Rest of World was up 5%, chiefly on good growth in Canada.
Revenue in the US was affected by generic competition for Arimidex, Pulmicort Respules and Toprol-XL, as well as the absence of H1N1 pandemic influenza vaccine revenue that benefited the third quarter 2009.
US revenue was down 13% in the third quarter.
AstraZeneca has posted a net profit of $1.55bn for the third quarter of 2010, compared to $2.12bn for the same period in 2009.
Operating profit was $2.41bn, compared to $3.2bn for the comparable period in 2009.
The third quarter was affected by legal provisions totaling $473m in relation to ongoing antipsychotic drug Seroquel litigation case.
AstraZeneca was also hit by a $128m impairment charge taken from ending development of lesogaberan, also known as AZD3355, an investigational compound for heartburn.
For the nine months ended 30 September 2010, the UK-based drugmaker has posted a revenue of $24.65bn, compared to $23.9bn for the year ago period.
Operating profit was $9.08bn, compared to $9.22bn for the year ago period.
AstraZeneca CEO David Brennan said that the company still expects demanding revenue and core EPS comparisons to carry into the fourth quarter.
"Nevertheless, based on the year to date performance and the outlook for the rest of the year, revenue for the full year is now likely to be broadly unchanged in constant currency terms compared with full year 2009," Brennan said.